Arjo ABOSTO:ARJO B -0.48%73 EBITDA Margin % is 16.90% as of Mar. 2026, which is 5% below its 10-year median of 17.85. GuruFocus rates OSTO:ARJO B with a GF Score™ of 73/100 and a GF Value™ of kr36.70 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 117 Medical Distribution companies, Arjo AB ranks better than 91.45% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Arjo AB's EBITDA for the
three
months ended in Mar. 2026 was kr456 Mil. Arjo AB's Revenue for the
three
months ended in Mar. 2026 was kr2,698 Mil. Therefore, Arjo AB's EBITDA margin for the quarter that ended in Mar. 2026 was 16.90%.
Arjo AB (OSTO:ARJO B) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Arjo AB EBITDA Margin % Related Terms
Arjo AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Arjo AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ARJO B vs MCK, CAH, COR: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Arjo AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arjo AB EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arjo AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Arjo AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arjo AB (OSTO:ARJO B) has a EBITDA Margin % of 16.90% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Arjo AB and its competitors. This is near median its historical median of 17.85. Over the past decade, Arjo AB's EBITDA Margin % has ranged from 13.14 to 22.40. According to the industry distribution chart, Arjo AB ranks #10 out of 117 companies in the Medical Distribution industry, placing it in the top 8.5%.
Is Arjo AB's EBITDA Margin % too high?
Arjo AB's current EBITDA Margin % of 16.90% is near median its 10-year median of 17.85. Over the past 10 years, this metric has ranged from a low of 13.14 to a high of 22.40. The Medical Distribution industry median EBITDA Margin % is 4.28. Arjo AB's value of 16.90% is 294.9% above this industry median. Based on the distribution chart, Arjo AB ranks #10 out of 117 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Arjo AB has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arjo AB's EBITDA Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Arjo AB ranks #10 out of 117 companies for EBITDA Margin %. This places Arjo AB in the top 9% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 4.28. Arjo AB's value of 16.90% is 294.9% above this benchmark. Historically, Arjo AB's own EBITDA Margin % has ranged from 13.14 to 22.40 over the past decade. While the company's 10-year median is 17.85 vs. the industry median of 4.28, Arjo AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.28, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arjo AB's current EBITDA Margin % of 16.90% is 294.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Arjo AB and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arjo AB's current EBITDA Margin % is 16.90%, which is near median its own 10-year median of 17.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arjo AB stock overvalued right now?
Based on GuruFocus' analysis, Arjo AB (OSTO:ARJO B) is currently considered Significantly Undervalued. The stock's GF Value™ is kr36.70, compared to a current price of kr24.84 — trading 32.3% below its estimated fair value. The current EBITDA Margin % is 16.90%, which is near median its 10-year median of 17.85 and 294.9% above the Medical Distribution industry median of 4.28. Arjo AB's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Arjo AB (OSTO:ARJO B), the current EBITDA Margin % is 16.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arjo AB (OSTO:ARJO B) Overvalued in 2026?
Based on GuruFocus' analysis, Arjo AB stock appears to be undervalued.
The current stock price of kr24.84 is trading 32.3% below its estimated GF Value™ of kr36.70.
GuruFocus considers Arjo AB to be Significantly Undervalued.
Key valuation signals for OSTO:ARJO B:
EBITDA Margin %: 16.90% (near median its 10-year median of 17.85)
GF Value™: kr36.70 vs. price of kr24.84 (32.3% below fair value)
Industry Position: 294.9% above the Medical Distribution median (#10 of 117)
No single metric tells the full story. See the OSTO:ARJO B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arjo AB is a supplier of medical devices, services, and solutions in Sweden. It serves its services to private and public institutions with acute care and long-term care. The company's offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention and diagnostics. The company includes segments: Global Sales, North America, Diagnostics.
73GF Score
Get the complete analysis for OSTO:ARJO B
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ARJO B has been successfully added to your 
